Additionally, TPX2 overproduction enhanced the TCF/LEF transcriptional activity, while the introduction of a Wnt/β-catenin pathway inhibitor partly mitigated the GC advancement enhanced by overproducing TPX2. This evidence concerns the gene TPX2 and gastric cancer.